PHARMAC - Latest News [Page 1]

PHARMAC approves largest single deal

Tuesday, 14 October 2014, 9:56 am | PHARMAC

Nearly 12,000 New Zealanders are set to benefit from major agreements that have been approved by PHARMAC. Agreements with two companies, Novartis and Biogen Idec, have been approved which will see 10 new medicines funded, and either reduced prices or ... More >>

Tender for generic medicines contributes $38 million savings

Monday, 18 August 2014, 3:25 pm | PHARMAC

New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender. The tender reached record levels this year, receiving nearly 3500 offers to supply pharmaceuticals from 54 companies. More >>

Savings for DHBs in medical equipment agreement

Friday, 15 August 2014, 10:54 am | PHARMAC

DHBs will save another $650,000 a year from lower priced wound care and surgery equipment through a new national PHARMAC agreement with a major medical device supplier. More >>

PHARMAC welcomes updated Medicines NZ Code of Practice

Wednesday, 13 August 2014, 9:57 am | PHARMAC

PHARMAC is welcoming the publication of an updated Medicines NZ Code of Practice (COP). The Code, now in its 16th edition, has been updated following feedback from stakeholders in the pharmaceutical sector, including PHARMAC. Chief executive Steffan ... More >>

PHARMAC looks to Pasifika community for advisory committee

Wednesday, 16 July 2014, 3:11 pm | PHARMAC

PHARMAC has appointed three new members to its Consumer Advisory Committee (CAC), all with strong links to the Pasifika community. More >>

Two new appointments to PHARMAC advisory committee

Wednesday, 18 June 2014, 10:04 am | PHARMAC

PHARMAC is welcoming the appointment of two new members to the Pharmacology and Therapeutics Advisory Committee (PTAC). PTAC provides PHARMAC with expert clinical advice on pharmaceutical funding applications being considered by PHARMAC, and other ... More >>

New treatment funded for severe gout

Wednesday, 21 May 2014, 2:24 pm | PHARMAC

New treatment funded for severe gout Patients with severe gout will soon have a new treatment option as PHARMAC will be funding febuxostat (Adenuric) from 1 June 2014. Gout is a painful form of arthritis, and is associated with high levels of uric acid ... More >>

Promoting competition key for high cost medicines

Tuesday, 8 April 2014, 11:12 am | PHARMAC

PHARMAC has announced its intention to test out a contestable fund for high cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. More >>

PHARMAC seeking public views on new decision criteria

Tuesday, 25 February 2014, 10:51 am | PHARMAC

PHARMAC is asking for people’s views on a proposed new framework for making pharmaceutical funding decisions. More >>

PHARMAC tender reveals vibrant market for pharmaceuticals

Wednesday, 12 February 2014, 10:46 am | PHARMAC

The number of companies bidding to be suppliers through the PHARMAC tender has grown to its largest size ever. PHARMAC runs a tender each year, asking pharmaceutical suppliers to provide pricing proposals for off-patent medicines listed on the Pharmaceutical ... More >>

Lung cancer treatment takes another forward step

Thursday, 9 January 2014, 8:50 am | PHARMAC

Improvements in lung cancer treatment are set to continue with a PHARMAC decision to extend funding for erlotinib (Tarceva) from 1 January 2014. More >>

Rotavirus, varicella vaccines added to national schedule

Tuesday, 17 December 2013, 11:44 am | PHARMAC

Rotavirus, varicella vaccines added to national immunisation schedule The addition of rotavirus vaccine to the list of funded vaccines will have a long-lasting positive effect on children’s health, says PHARMAC Medical Director Dr John Wyeth. PHARMAC ... More >>

PHARMAC declines eculizumab funding proposal due to price

Thursday, 12 December 2013, 2:41 pm | PHARMAC

An unreasonably high price means PHARMAC has decided not to approve funding for eculizumab, a treatment for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). More >>

New agreement provides new medicines, saves millions

Monday, 9 December 2013, 3:25 pm | PHARMAC

A new agreement with GlaxoSmithKline (GSK) will see two newly listed medicines, improved access to commonly used asthma inhalers, and millions of dollars of savings. More >>

Funding for new drug to treat rare bleeding condition

Monday, 9 December 2013, 1:11 pm | PHARMAC

PHARMAC has agreed to fund a new drug to treat a rare and potentially fatal blood disorder. People with idiopathic thrombocytopenic purpura (ITP) have low numbers of the blood platelets that help with clotting. More >>

Medicine prescribing hits new high as PHARMAC role expands

Thursday, 5 December 2013, 11:26 am | PHARMAC

Medicine prescribing hits new high as PHARMAC role expands New Zealanders have gained greater access to medicines in 2013, and record numbers of New Zealanders received funded medicines in the past year. PHARMAC’s 2012/13 Annual Review, published today, ... More >>

PHARMAC proposing to add to national immunisation schedule

Thursday, 7 November 2013, 12:58 pm | PHARMAC

A vaccine for the gastric infection rotavirus and protection from varicella for the most vulnerable people are among proposed changes to the national immunisation schedule that PHARMAC is seeking feedback on. More >>

PHARMAC seeking input on hospital medical devices work

Friday, 18 October 2013, 10:05 am | PHARMAC

From cotton tips to MRI machines – a huge variety of medical devices are purchased by our hospitals to help diagnose and treat patients. Now PHARMAC is seeking further input as it decides how to apply its existing approach to managing hospital medical ... More >>

Influenza vaccine supply secured for next three years

Thursday, 17 October 2013, 11:14 am | PHARMAC

17 October, 2013 Influenza vaccine supply secured for next three years PHARMAC has secured the national supply of influenza vaccines for the next three years. Today PHARMAC announced that GSK and Abbott Pharmaceuticals will be the suppliers of influenza ... More >>

First funded treatment for motor neurone disease

Monday, 30 September 2013, 2:02 pm | PHARMAC

The first funded pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease, will become available from 1 October 2013. More >>

 

 

InfoPages Links

 
 
 
 
 

LATEST HEADLINES

 
 
 
InfoPages
Search Scoop  
 
 
Powered by Vodafone
NZ independent news